Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Genetically proxied PCSK9 inhibition provides indication of lower prostate cancer risk: a Mendelian randomization study

medRxiv(2022)10.1101/2022.04.18.22274003Source: DataRank Database

Genetically proxied PCSK9 inhibition provides indication of lower prostate cancer risk: a Mendelian randomization study is a research paper published in medRxiv (2022). On theSindex it has a DataRank of 0. It has been cited 2 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access2 citations

Download PDF

Cite:

Linked data & code

refsnp doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)OA: greenTopics (26)IDs (PubMed, OpenAlex)Annotations (2)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (8)

James Yarmolinsky ORCID,Dipender Gill ORCID,Caroline J. Bull ORCID,Claire M. Perks ORCID,George Davey Smith ORCID

Live enrichment

PubMed:19022398 OpenAlex:https://openalex.org/W4224243618

Wellcome Trust

Grant: 108902/Z/15/Z

UK Research and Innovation

Grant: MC_UU_00011/4

Data mining epidemiological relationships: integration of causal analysis with published evidence

Wellcome Trust

Grant: 108902

Molecular, Genetic and Lifecourse Epidemiology

UK Research and Innovation

Grant: MC_UU_00011/1

Mendelian randomization to hypothesis-free causal inference

greenLicense: cc-by

repositoryhttps://www.medrxiv.org/content/medrxiv/early/2022/04/19/2022.04.18.22274003.full.pdf

GREENhttps://www.medrxiv.org/content/medrxiv/early/2022/04/19/2022.04.18.22274003.full.pdf

repositoryhttps://www.medrxiv.org/content/medrxiv/early/2022/04/19/2022.04.18.22274003.full.pdf

publisherhttps://syndication.highwire.org/content/doi/10.1101/2022.04.18.22274003

repositoryhttps://doi.org/10.1101/2022.04.18.22274003

Fields of Study

Lipoproteins and Cardiovascular HealthGenetic Associations and EpidemiologyCancer, Lipids, and MetabolismMedicine0301 basic medicine0303 health sciences03 medical and health sciences

Keywords

Mendelian randomizationGenome-wide association studySingle-nucleotide polymorphismPCSK9Prostate cancerOncologyMedicineInternal medicineConfoundingOdds ratioBiologyGeneticsCancerCholesterolLipoproteinGenotypeGeneLDL receptorGenetic variants

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Genetically proxied PCSK9 inhibition provides indication of lower prostate cancer risk: a Mendelian randomization study

FAIR Checklist

Authors (8)

Funding (4 grants)

Open Access

Topics

Annotations (Europe PMC)